MZMichal Zabrodsky

Michal Zabrodsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michal Zabrodsky has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bioethics committee approvals in multicentre laryngology research across Europe: the European Laryngological Society’s consensus on legal basis and quality assurance

    by Malgorzata Wierzbicka, Michal Zabrodsky, Chadwan Al Yaghchi, Christoph Arens, Gauthier Desuter, Necati Enver, Ahmed Geneid, Renata Kopczyk, Isabel Garcia Lopez, Alexia Mattei, et al.

    To describe European legal foundations, governance structures, and quality assurance mechanisms for bioethics committee approvals in multicenter laryngology research, and present a consensus framework to harmonize practice across Europe. An expert panel used the Nominal Group Technique to define scope, review supranational and national regulations (including Regulation (EU) 536/2014 and GDPR considerations), and identify practical barriers in multicenter/multinational laryngology research. Consensus rounds prioritized reproducibility, feasibility, and harmonization of ethics review processes across jurisdictions. Regulatory context combines EU Regulation 536/2014 and GDPR with substantial national heterogeneity in REC/IRB structure and procedures. Core challenges include: (i) heterogeneity of documentation and approvals; (ii) ambiguity about single vs. multiple REC approvals in multicenter studies; (iii) limited guidance for registry-based and real-world data designs; and (iv) variable integration of data protection and ethics review. Key recommendations: clarify when single-country versus cross-border REC approvals are required; standardize documentation templates and timelines; align consent and data-handling with ethics review; provide governance for emerging study designs and biobanking; and promote EUlevel coordination to harmonize practices. National variation challenges multicenter laryngology research in Europe. The European Laryngological Society provides a consensus framework to guide legal bases and quality assurance of REC approvals, aiming to improve efficiency, consistency, and ethical compliance.

  • Open Access

    Off-label drugs in laryngology– what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society

    by Malgorzata Wierzbicka, Renata Kopczyk, Michal Zabrodsky, Cesare Piazza, Gauthier Desuter, Peter Klussmann, Ahmed Geneid, Frederic Dikkers

    Purpose: Off-label drugs are being used in laryngology. Prescribing of a medicinal product is a decision taken within the relationship between a patient and his/her treating health care provider (HCP). The purpose of this article is to discuss the medicolegal aspects of off-label drug use, to provide recommendations for obtaining informed patient consent for off-label treatment and to propose the place and role of scientific societies and specialist boards in shaping good practices in this area. The final aim is to present recommendations concerning off-label usage and propose special clauses in informed patients consent. Methods: The literature was reviewed regarding off-label applications in laryngology. Practical information on off-label use in various EU countries was collected. Results: Registration data and pharmacokinetics of cidofovir, bevacizumab, Gardasil®, hyaluronic acid and mitomycin are provided. Off-label prescribing is not prohibited by EU law. Informed consent to treatment with an off-label drug exists in all EU countries. The risk that a court will accept liability of a HCP in case of off-label prescribing is higher than in case of on-label prescribing. If a HCP is held liable for the outcome of a medical treatment, the approval by the competent authorities and professional guideline is a strong defense. Conclusion: A patient’s precise, explicit consent for the procedures including off-label drugs administration is mandatory. The second prerequisite is defining a need for creating based on recommendations by national or international scientific societies.


  • Open Access

    Comparison of narrow-band imaging with autofluorescence imaging for endoscopic detection of squamous cell carcinoma of the tonsil

    by J. Syba, K. Trnkova, L. Dostalova, M. Votava, E. Lukesova, S. Novak, M. Kana, M. Tesarova, M. Zabrodsky, J. Plzak, et al.

    Purpose: Early detection of mucosal neoplastic lesions is crucial for a patient’s prognosis. This has led to the development of effective optical endoscopic diagnostic methods such as narrow band imaging (NBI) and autofluorescence (AFI). Independent of each other, both of these methods were proven useful in the detection of mucosal neoplasias. There are limited reported data comparing both methods for oropharyngeal cancer diagnostics. The aim of the study was to compare NBI and AFI endoscopic visualization of signs in identifying tonsillar squamous cell carcinoma (SCC) and assessing its extent and to determine whether the score was related to the evaluator’s experience. Methods: Patients with tonsillar SCC underwent endoscopic pharyngeal examination using NBI and AFI. Fiftyseven video sequences of examinations of lesions proven to be SCC were evaluated by three reviewers. The accuracy of determination of lesion extent and visualization of its endoscopic signs of malignancy were evaluated. Results: Endoscopic visualization of tumour spread was significantly better using AFI than NBI (p = 0.0003). No significant difference was found between NBI and AFI in the visualization of endoscopic malignancy determining signs (p = 0.1405). No significant difference was found among the three reviewers in the visualization of tumour spread and for identifying malignancy-determining signs in NBI endoscopy or AFI endoscopy. Conclusions: The results show that AFI obtained better results for assessing the extent of tonsillar cancers than NBI. Both methods were proven to be equal in the visualization of endoscopic malignancy-determining signs. Both are useful even for less experienced evaluators.


  • The professional journal Otorhinolaryngology and Phoniatrics celebrates 70 years

    by Jaromír Astl, Michal Zábrodský, David Kalfeřt

  • Experience with follow-up strategy in selected patients with Warthin tumour diagnosed by ultrasound-guided fine-needle aspiration biopsy (FNAB)

    by Alžběta Fíková, Martin Kuchař, David Kalfeřt, Lucie Dostálová, Jan Balko, Michal Zábrodský, Jan Plzák

    Purpose Warthin tumour (WT) management options comprise surgery or follow-up. The purpose of this study was to asses our experience with the follow-up strategy in selected patients with an ultrasound-guided fine-needle aspiration biopsy (FNAB) showing WT. Methods We performed a retrospective analysis of patients diagnosed with WT using FNAB between 1.1.2006 and 31.12.2019. Patients were divided into three groups according to the therapeutic approach—immediate surgery, follow-up or surgery and follow-up. Results 323 patients were diagnosed with WT and met the study’s inclusion criteria (154 women, 47.7% and 169 men, 52.3%). 192 patients were operated right after the diagnosis, 109 patients were observed with their first detected tumour and 22 patients had parotid WT surgery and were in the wait-and-scan protocol with a contralateral tumour, recurrence or both. The growth rate (GR) of observed WT was highly variable (mean GR 1.0 mm/year (5%), median GR 0.8 mm (9%), range − 19.7 to +20.0 mm/year). From 131 patients in the follow-up group, 19 patients underwent surgery and definitive histology revealed 17 WTs and 2 adenocarcinomas. However, these 2 patients had changes in sonographic findings at their next control. The mean observation time was 44.7 months (range 12–138 months) in patients followed exclusively at our institution and 50.9 months (range 12–110 months) in patients observed in cooperation with an otorhinolaryngologist at the patients’ place of residence. Conclusion Ultrasound-guided FNAB is an accurate and simple method in WT diagnosis and based on its result a follow-up strategy can be chosen for selected patients with WT.


  • Open Access

    Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors

    by Robert Pola, Eliška Böhmová, Marcela Filipová, Michal Pechar, Jan Pankrác, David Větvička, Tomáš Olejár, Martina Kabešová, Pavla Poučková, Luděk Šefc, et al.

    This report describes the design, synthesis and evaluation of tumor-targeted polymer probes to visualize epidermal growth factor receptor (EGFR)-positive malignant tumors for successful resection via fluorescence guided endoscopic surgery. Fluorescent polymer probes of various molecular weights enabling passive accumulation in tumors via enhanced permeability and retention were prepared and evaluated, showing an optimal molecular weight of 200,000 g/mol for passive tumor targeting. Moreover, poly(N-(2-hydroxypropyl)methacrylamide)-based copolymers labeled with fluorescent dyes were targeted with the EGFR-binding oligopeptide GE-11 (YHWYGYTPQNVI), human EGF or anti-EGFR monoclonal antibody cetuximab were all able to actively target the surface of EGFR-positive tumor cells. Nanoprobes targeted with GE-11 and cetuximab showed the best targeting profile but differed in their tumor accumulation kinetics. Cetuximab increased tumor accumulation after 15 min, whereas GE 11 needed at least 4 h. Interestingly, after 4 h, there were no significant differences in tumor targeting, indicating the potential of oligopeptide targeting for fluorescence-navigated surgery. In conclusion, fluorescent polymer probes targeted by oligopeptide GE-11 or whole antibody are excellent tools for surgical navigation during oncological surgery of head and neck squamous cell carcinoma, due to their relatively simple design, synthesis and cost, as well as optimal pharmacokinetics and accumulation in tumors.


  • Efficacy of Transnasal Flexible Videoendoscopy With Narrow Band Imaging for Follow‐Up of Patients After Transoral Laser Cordectomy

    by Petr Lukes, Michal Zabrodsky, Jaroslav Syba, Eva Lukesova, Michal Votava, Jan Plzak

    Background and Objectives: Transoral laser surgery is the optimal surgical treatment modality for the early stages of glottic cancer. To allow for further treatment to be as effective and as minimal as possible, persistent or recurrent tumors should be detected very soon. The main aim is to minimize the risk of necessity of performing a total laryngectomy. Flexible videoendoscopy with narrow band imaging (NBI) was recommended by the European Laryngological Society as a diagnostic method for the follow‐up of patients treated for laryngeal cancer. Nevertheless, the efficacy of this technique has not been extensively studied in patients after transoral laser cordectomies for vocal fold cancer. The aim of this study was to evaluate the efficacy of in‐office transnasal NBI flexible videoendoscopy in the follow‐up of patients after transoral laser cordectomy for glottic cancer. We also focused on describing the specific characteristics of recurrent tumor appearance.Materials and Methods: The presented study was conceived as a prospective study. Ninety‐four consecutive patients who underwent transoral laser cordectomy for severe dysplasia, Tis, T1, and T2 glottic cancer in the period from June 2010 to August 2015 were enrolled in the study. All patients were postoperatively regularly followed using transnasal videoendoscopic examinations with NBI. Whenever a suspect lesion was identified during in‐office examination, its nature was proven histologically.Results: We discovered 23 suspect findings in 21 patients by means of flexible videoendoscopy with NBI. Fifteen (65.2%) of them were histologically confirmed as recurrent tumors, whereas in 8 (34.8%) of them, the recurrent tumor was not proven. In two patients, the recurrent tumor was evident on computed tomography or magnetic resonance imaging, but NBI endoscopy did not reveal relapsing disease. The rest (71 patients) were considered true negative. Of the 15 recurrent tumors detected by NBI‐coupled videoendoscopy, 8 (53.3%) were identified as submucosal masses with nonsignificant or no vascular changes, 4 (26.7%) were noted as the progression of leukoplakia without visible vascular changes, only 2 (13.3%) showed typical vascular changes, and, in 1 (6.7%) case, evident, significantly exophytic tumor with pathological vascularization was discovered. The sensitivity, specificity, and positive and negative predictive values of the in‐office transnasal videolaryngoscopy with NBI were calculated to be 88%, 92%, 71%, and 97%, respectively.Conclusions: The results of the study demonstrate that transnasal endoscopy with NBI in an outpatient setting is an excellent method for the follow‐up of patients after transoral laser cordectomy for glottic cancer. The method achieves high sensitivity, specificity, and negative predictive value and a slightly low positive predictive value. Nevertheless, we must bear in mind that recurrent tumors after previous endoscopic resection may have a completely different appearance than new tumors originating from previously untreated tissues. Lasers Surg. Med.


  • Baha implant as a hearing solution for single-sided deafness after retrosigmoid approach for the vestibular schwannoma: surgical results

    by Jan Boucek, Jan Vokral, Libor Cerny, Martin Chovanec, Jiří Skrivan, Eduard Zverina, Jan Betka, Michal Zabrodsky

    Skull base tumors and, in particular, vestibular schwannoma (VS) are among the etiological reasons for single-sided deafness (SSD). Patients with SSD have problems in understanding speech in a noisy environment and cannot localize the direction of sounds. Baha is one of the most frequently used systems for SSD compensation. Out of 38 patients with SSD after retrosigmoid removal of VS who underwent testing with Baha softband, 16 were satisfied and were indicated for Baha implantation. Two surgical approaches have been used—the Nijmegen linear incision technique with subdermal thinning (Group I, implant BI300) and fast surgery technique without subdermal thinning (Group II, implant BIA400). The duration of the surgery, the implant stability measured by Ostell, and skin or soft tissue reactions in long range follow-up were evaluated and compared between Group I and II. There was a difference in duration of surgery, in Group II procedures averaged significantly faster (p > 0.001). In both groups, there was a similar trend of the gradual increase of implant stability. In the Group I and II, there was comparable rate of the skin or soft tissue reactions grade 0, I, II, or III. We have proved Baha to be a suitable possibility for SSD patients after the removal of VS, regardless of the approach. After the retrosigmoid approach to the VS, the key step of Baha implantation must be to reach intact healthy bone to avoid implantation into scar tissue.


  • Baha implant as a hearing solution for single-sided deafness after retrosigmoid approach for the vestibular schwannoma: audiological results

    by Jan Bouček, Jan Vokřál, Libor Černý, Martin Chovanec, Michal Zábrodský, Eduard Zvěřina, Jan Betka, Jiří Skřivan

    Skull base tumors and, in particular, vestibular schwannoma (VS) are among the etiological reasons for single-sided deafness (SSD). Patients with SSD have problems in understanding speech in a noisy environment and cannot localize the direction of sounds. For the majority, this is the handicap for which they try to find a solution. Apart from CROS hearing aids, Baha is one of the most frequently used systems for SSD compensation. 38 patients with single-sided deafness after retrosigmoid removal of a vestibular schwannoma underwent testing with a Baha softband from September 2010 to August 2014. Sixteen patients (42 %) finally decided to accept Baha implantation. Subjective experience with the Baha softband was evaluated by patients using the BBSS questionnaire immediately after testing. Objective evaluation of the effect was performed as a measurement of the sentence discrimination score in noise and side horizontal discrimination without a Baha and 6 weeks and 12 months after a sound processor fitting. There was a significant improvement in sentence discrimination in the 6 week (64.0 %) and 1 year (74.6 %) interval of follow-up in comparison with understanding without Baha (24.0 %, p = 0.001) in situations when sentences are coming from the side of the non-hearing ear and noise contralaterally with SNR −5 dB. Baha can significantly improve sentence discrimination in complex-listening situation in patients with SSD after the VS surgery.


  • Immune System in Patients with Head and Neck Carcinoma

    by Simona Partlová, Jan Bouček, Kamila Kloudová, Michal Zábrodský, Radek Špíšek, Anna Fialová

    The insight into the biological nature of head and neck squamous cell carcinoma has evolved significantly in the last few years. Tobacco use and alcohol consumption are proven risk factors of head and neck squamous cell carcinoma. Cancer patients possessing such a tumor are generally elderly, mostly in fifth or sixth decade of life. In addition, significant association of head and neck squamous cell carcinoma with infection by human papillomavirus (HPV) was proven. HPV is now considered to be one of the most important risk factors, particularly for oropharyngeal carcinoma. HPV positive tumors of oropharynx are associated with significantly better prognosis. Experimental and clinical data indicate that HPV positive and HPV negative tumors can be considered as two different entities and it has not been clarified which factors are crucial for better prognosis of HPV positive tumors. The character of immune reaction, which contributes to distinct prognosis, may be one of the important factors. This review summarizes current knowledge concerning various aspects of antitumor immune responses in HPV positive and HPV negative tumors. Recent studies have shown that a broad repertoire of tumor infiltrating HPV specific T-cells is detectable in almost all patients with HPV positive tumors. Despite this, there is a development of tumor, which may be facilitated by abnormalities in antigen processing, T-cell dysfunction or prevalence of immunosuppressive cells. Nonetheless, the immunologic profile of HPV positive vs. HPV negative head and neck squamous cell carcinoma is associated with better outcome, and HPV specific immune response is suggested to play an essential role in the better response to conventional therapy of HPV positive patients. We also discuss HPV specific antitumor immunotherapy approaches, which are now tested in clinical trials.